STOCK TITAN

Rhythm Pharmaceuticals officer proposes $5.35M stock sale

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

Joseph J. Shulman, an officer of Rhythm Pharmaceuticals, Inc. (RYTM), reported a proposed sale of 45,921 common shares with an aggregate market value of $5,354,847.81, with an approximate sale date of November 18, 2026. The acquisition table lists 40,467 shares acquired through stock-option exercise on November 18, 2026 and 5,454 restricted stock units acquired February 1, 2025; the remarks separately state that the securities to be sold were acquired upon restricted-stock-unit vesting from February 1 through February 16, 2025.

Proposed sale 45,921 common shares Approximate sale date: November 18, 2026
Aggregate market value $5,354,847.81 For the proposed sale
Shares outstanding 69,330,906 common shares Listed in the form
Shares acquired through stock-option exercise 40,467 shares Acquisition table date: November 18, 2026
Restricted stock units acquired 5,454 units Acquisition table date: February 1, 2025
Exercise of Stock Options financial
"Nature of Acquisition Transaction: Exercise of Stock Options"
Restricted Stock Units financial
"Nature of Acquisition Transaction: Restricted Stock Units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Rule 10b5-1 regulatory
"Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RYTM shares did Joseph J. Shulman propose to sell?

The proposed sale covers 45,921 common shares with an aggregate market value of $5,354,847.81, with an approximate sale date of November 18, 2026.

What Rule 10b5-1 date is listed for Joseph J. Shulman's RYTM sale notice?

The form lists December 15, 2025 as the plan adoption or instruction date in its Rule 10b5-1 field.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading